05 How are we doing in controlling SLE activity?

Describe MRAs, particularly non-steroidal agents, may offer additional proteinuria reduction in CKD, but their use in lupus nephritis is not standard and should be individualised due to risks of hyperkalemia and acute kidney injury REFERENCES

Authors

Institutions

Publication Details

Journal
Abstracts
Published
2025-10-01
DOI
https://doi.org/10.1136/lupus-2025-la.5
Primary Topic
Substance Abuse Treatment and Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

05 How are we doing in controlling SLE activity?

Sandra Navarra
Abstracts
Substance Abuse Treatment and Outcomes
article

05 How are we doing in controlling SLE activity?

Sandra Navarra
article en

Abstract

Describe MRAs, particularly non-steroidal agents, may offer additional proteinuria reduction in CKD, but their use in lupus nephritis is not standard and should be individualised due to risks of hyperkalemia and acute kidney injury REFERENCES

Abstracts
University of Santo Tomas (PH)
Openalex Percentile: Top 62%
Substance Abuse Treatment and Outcomes
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

05 How are we doing in controlling SLE activity? — Sandra Navarra · Abstracts (2025) | TGRS Research Map | TGRS